Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Curtis Johnson

Facial Plastic Surgery Plantation, FL Doctor of Osteopathy

NPI 1427042852 CMS profile 337170

220 Sw 84Th Ave, Suite 101, Plantation, FL 33324

Open in the dashboard

General payments

$37,227

77 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$335,678 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Curtis Johnson of Plantation, FL is reported in the CMS Open Payments database as having received $37,227 across 77 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $335,678 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $92 4
2024 General $2,941 4
2023 General $7,448 22
2022 General $8,331 16
2021 General $2,017 5
2020 General $16,123 16
2019 General $274 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Curtis Johnson
  • Facial Plastic Surgery median
  • Middle half of Facial Plastic Surgery
  • National median

In program year 2025, general payments to Curtis Johnson were reported at $92. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.

Show as a table
Year Curtis Johnson Facial Plastic Surgery median Middle half National median
2019 $274 $225 $92–$651 $163
2020 $16,123 $132 $45–$323 $114
2021 $2,017 $186 $67–$558 $132
2022 $8,331 $218 $83–$594 $149
2023 $7,448 $237 $94–$564 $160
2024 $2,941 $233 $104–$575 $164
2025 $92 $270 $116–$579 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Aerin Medical Inc. $36,452 54 payments
  2. Inspire Medical Systems, Inc. $200 1 payment
  3. Stryker Corporation $161 7 payments
  4. ALK-Abello, Inc $94 1 payment
  5. OptiNose US, Inc. $90 4 payments
  6. Genzyme Corporation $58 2 payments
  7. GlaxoSmithKline, LLC. $54 3 payments
  8. kaleo, Inc. $37 2 payments
  9. Acclarent, Inc $29 1 payment
  10. Smith+Nephew, Inc. $29 1 payment
  11. Other $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $34,000 21 payments
  2. Honoraria $2,000 3 payments
  3. Food and Beverage $1,200 52 payments
  4. Education $28 1 payment
Products named General payments · program years 2019–2025
  1. VIVAER STYLUS $19,357 30 payments
  2. VivAer $16,000 7 payments
  3. RhinAer $16,000 7 payments
  4. RHINAER STYLUS $10,957 21 payments
  5. INSPIRE $200 1 payment
  6. Odactra $94 1 payment
  7. Xhance $90 4 payments
  8. ENTELLUS - XPRESS ENT DILATION SYSTEM $85 2 payments
  9. DUPIXENT $58 2 payments
  10. NUCALA $54 3 payments
  11. Other $296 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

1,282

Median for Otolaryngology: 297

Drug cost

$21,986

Median for Otolaryngology: $6,314

Branded share of claims

2.4%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ipratropium Bromide Generic 566 $13,004
Fluticasone Propionate Generic 231 $3,561
Epinephrine Generic 11 $1,818
Montelukast Sodium Generic 220 $1,302
Neomycin-Polymyxin-Hc Neomycin/Polymyxin B/Hydrocort Brand 19 $1,020
Methylprednisolone Generic 142 $843
Omeprazole Generic 13 $110
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $96
Clindamycin Hcl Generic 20 $94
Azithromycin Generic 15 $73

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$156,390

Medicare's payments for the services billed

Medicare patients

366

Average age 76

Services billed

2,738

220 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 35%
Diabetes 34%
Chronic kidney disease 26%
Osteoporosis 23%
COPD 21%
Depression 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Facial Plastic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record